Publications by authors named "S Girgis"

Background: Unrecognised obstructive sleep apnoea (OSA) has been associated with adverse cardiorespiratory perioperative outcomes. However, with changing anaesthetic and perioperative management, there is ongoing uncertainty about the importance of OSA as a risk factor for post-operative complications.

Methods: A cohort study involving subjects undergoing elective surgery was conducted.

View Article and Find Full Text PDF

Inferior vena cava (IVC) leiomyosarcomas are rare smooth muscle neoplasms that account for 0.5% of adult soft tissue sarcomas. They present with nonspecific symptoms and have poor prognosis.

View Article and Find Full Text PDF

Children's Oncology Group study AALL1931 investigated the efficacy and safety of recombinant Erwinia asparaginase (JZP458) in patients with acute lymphoblastic leukemia/lymphoblastic lymphoma and hypersensitivity reactions/silent inactivation to Escherichia coli-derived asparaginases. Each pegylated Escherichia coli asparaginase dose remaining in a patient's treatment plan was replaced by intramuscular (IM) or IV JZP458 (6 doses) administered Monday/Wednesday/Friday (MWF). Three IM cohorts (1a [25 mg/m2 MWF], n = 33; 1b [37.

View Article and Find Full Text PDF

Sarcoidosis is a multisystem disease characterized by non-caseating granulomatous organ infiltration. We describe an atypical presentation of sarcoidosis in a 43-year-old male presenting with fatigue and shortness of breath. He had a preceding history of recurrent venous thromboembolism (VTE), hemolytic anemia, cirrhosis, peripheral neuropathies, and calcium deposition, which pre-dated hypercalcemia; he was later diagnosed with IgA nephropathy.

View Article and Find Full Text PDF
Article Synopsis
  • Cytokine release syndrome, often linked to T-cell therapies like talquetamab, causes an increase in interleukin-6 (IL-6), which might inhibit certain liver enzymes (cytochrome P450).
  • The study aimed to assess how elevated IL-6 affects the metabolism of other drugs by looking at both standard and extreme IL-6 levels after talquetamab treatment.
  • Results showed that while normal IL-6 levels had no significant impact on drug interactions, elevated IL-6 could moderately affect specific liver enzymes, with potential effects peaking 7 to 9 days after the start of treatment.
View Article and Find Full Text PDF